D
Diego Aparecido Rios Queiroz
Publications - 1
Citations - 326
Diego Aparecido Rios Queiroz is an academic researcher. The author has contributed to research in topics: Randomized controlled trial & Rivaroxaban. The author has an hindex of 1, co-authored 1 publications receiving 64 citations.
Papers
More filters
Journal ArticleDOI
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Renato D. Lopes,Pedro Gabriel Melo de Barros e Silva,Remo H.M. Furtado,Ariane Vieira Scarlatelli Macedo,Bruna Bronhara,Lucas P. Damiani,Lilian Mazza Barbosa,Júlia de Aveiro Morata,Eduardo Ramacciotti,Priscilla de Aquino Martins,Aryadne Lyrio de Oliveira,Vinicius Santana Nunes,Luiz Eduardo Fonteles Ritt,Ana Thereza Rocha,Lucas Tramujas,Sueli V Santos,Dario Rafael Abregu Diaz,Lorena Souza Viana,Livia Maria Garcia Melro,Mariana Silveira de Alcântara Chaud,Estêvão Lanna Figueiredo,Fernando Carvalho Neuenschwander,Marianna Deway Andrade Dracoulakis,Rodolfo Godinho Souza Dourado Lima,Vicente C.S. Dantas,Anne Cristine Silva Fernandes,Otavio Gebara,Mauro E. Hernandes,Diego Aparecido Rios Queiroz,Viviane C Veiga,Manoel Fernandes Canesin,Leonardo Meira de Faria,Gilson Soares Feitosa-Filho,Marcelo Basso Gazzana,Idelzuíta Leandro Liporace,Aline de Oliveira Twardowsky,Lilia Nigro Maia,Flávia Ribeiro Machado,Alexandre de Matos Soeiro,Germano Emílio Conceição-Souza,Luciana Armaganijan,Patrícia O. Guimarães,Regis Goulart Rosa,Luciano Cesar Pontes Azevedo,John H. Alexander,Alvaro Avezum,Alexandre Biasi Cavalcanti,Otavio Berwanger +47 more
TL;DR: In this paper, the authors compared the efficacy and safety of therapeutic versus prophylactic anticoagulation in patients hospitalised with COVID-19 in 31 sites in Brazil, and found that in the case of stable patients, in-hospital oral rivaroxaban (20 mg or 15 mg daily) or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0·3-0·7 IU/mL anti-Xa concentration) for clinically unstable patients, followed